Dandrid

Dandrid Tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.

Dandrid Tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid.

Dandrid Tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin.

Topical treatment of tinea corporis, tinea cruris, tinea pedis, pityriasis versicolor & cutaneous candidiasis. Treatment & prevention of relapse of fungal skin infections eg dandruff, seborrhoeic dermatitis & pityriasis versicolor.

Apply liberally on the affected areas, gently massage, leave for 2-3 hrs & then wash with water. It can also be left overnight for 8 hrs & washed in the morning. Lotion to be applied 2-4 times a wk with a gap of 2 days.

Coadministration of terfenadine or astemizole with Dandrid Tablets is contraindicated. Concomitant administration of Dandrid Tablets with cisapride, with oral triazolam is contraindicated. Dandrid is contraindicated in patients who have shown hypersensitivity to the drug.

Dandrid is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of Dandrid Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.

Dandrid Tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine.

Dandrid inhibits the metabolism of astemizole. Dandrid potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.

Dandrid Tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.

Coadministration of Dandrid Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.

It is, therefore, advisable to monitor digoxin concentrations in patients receiving Dandrid.

When taken orally, imidazole compounds like Dandrid may enhance the anticoagulant effect of coumarin-like drugs.

a potential interaction involving the latter agents when used concomitantly with Dandrid Tablets (an imidazole) can not be ruled out.

Concomitant administration of Dandrid Tablets with phenytoin may alter the metabolism of one or both of the drugs.

Concomitant administration of rifampin with Dandrid Tablets reduces the blood levels of the latter. INH (isoniazid) is also reported to affect Dandrid concentrations adversely.

In rare cases, anaphylaxis has been reported after the first dose. However, the most frequent adverse reactions were nausea and/or vomiting in approximately 3%, abdominal pain in 1.2%, pruritus in 1.5%, and the following in less than 1% of the patients: headache, dizziness, somnolence, fever and chills, photophobia, diarrhea, gynecomastia, impotence, thrombocytopenia, leukopenia, hemolytic anemia, and bulging fontanelles. In contrast, the rare occurrences of hepatic dysfunction require special attention. Skin irritation-burning sensation, pruritus, dermatitis Rarely, local burning sensation, itch, irritation, oily/dry hair & scalp, increased hair loss, abnormal hair texture, scalp pustules.